Video Experimental Relacionado

Updated: Feb 20, 2026

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

Dirigirse a la vía cGAS-STING-TBK1 en la terapia contra el cáncer

Leyao Jiang¹, Ying Zhong¹, Zilong Zhang¹

¹School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation, Ministry of Education, Yantai University, Yantai, China.

Future medicinal chemistry

|February 19, 2026

Resumen

Los avances en inmunoterapia aprovechan la vía cGAS-STING-TBK1 para el tratamiento del cáncer. Comprender su doble papel en la inmunidad es clave para desarrollar fármacos anticancerosos novedosos y potentes.

Área de la Ciencia:

Inmunología
Biología Molecular
Oncología

Sus antecedentes:

Los avances recientes en inmunoterapia se centran en la modulación de la señalización inmunitaria innata.
La vía cGAS-STING-TBK1 es central para la detección de ADN citoplásmico y la inmunidad antitumoral.
Esta vía tiene un doble papel: promueve la inmunidad cuando se activa adecuadamente, pero ayuda a la progresión tumoral cuando se sobreactiva o es disfuncional.

Objetivo del estudio:

Analizar los mecanismos moleculares de la vía cGAS-STING-TBK1.
Elucidar las funciones biológicas de la vía en el cáncer.
Revisar el progreso de la investigación sobre fármacos dirigidos a esta vía.

Principales métodos:

Análisis en profundidad de los mecanismos moleculares.
Revisión de las funciones biológicas en la oncogénesis.
Examen de la investigación actual sobre fármacos dirigidos.

Principales resultados:

Se destaca el doble papel de la vía cGAS-STING-TBK1 en la inmunidad antitumoral.
La activación adecuada de la vía mejora las respuestas inmunitarias contra el cáncer.
La activación disfuncional o excesiva puede promover el crecimiento tumoral.

Conclusiones:

La actuación sobre la vía cGAS-STING-TBK1 ofrece nuevas vías terapéuticas para el cáncer.
Se necesita más investigación para desarrollar fármacos potentes mediante la comprensión de las funciones únicas de la vía.
La modulación de esta vía es crucial para una inmunoterapia eficaz contra el cáncer.

Palabras clave:

Inmunoterapia vía cGAS-STING-TBK1 fármacos dirigidos inmunidad tumoral interferón tipo I

Más Videos Relacionados

Combined Conditional Knockdown and Adapted Sphere Formation Assay to Study a Stemness-Associated Gene of Patient-derived Gastric Cancer Stem Cells

Combined Conditional Knockdown and Adapted Sphere Formation Assay to Study a Stemness-Associated Gene of Patient-derived Gastric Cancer Stem Cells

Published on: May 9, 2020

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Videos de Conceptos Relacionados

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Drugs that Stabilize Microtubules

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

M-Cdk Drives Transition Into Mitosis

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...